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The intracellular penetration and activity of DX-619 in human polymorphonuclear leukocytes have been
evaluated. DX-619 reached intracellular concentrations 10 times higher than the extracellular concentrations
reached. Uptake was rapid, reversible, nonsaturable, and affected by environmental temperature, some met-
abolic inhibitors, and a soluble membrane activator. DX-619 showed intracellular activity against Staphylo-
coccus aureus.
The intracellular penetration and activities of antimicrobial
agents are important considerations in the treatment of infec-
tions due to intracellular pathogens. Quinolones are able to
penetrate and concentrate intracellularly, showing activities
against intracellular pathogens (1, 6–8). DX-619 is a novel
des-fluoro(6) quinolone that displays good activity against mul-
tiresistant gram-positive bacteria (2, 3). This quinolone also
manifests an exceptionally low frequency of selection of resis-
tant mutants (16, 17). One animal model shows that DX-619
could be a promising candidate for treating community-ac-
quired respiratory infections (4). Its clinical role will be better
appreciated when human pharmacokinetics data have been
published. The purpose of this study was to evaluate the up-
take of DX-619 by human polymorphonuclear leukocytes
(PMNs). The mechanism involved in the penetration of this
agent into human PMNs and its intracellular activity against
Staphylococcus aureus were also evaluated.
The uptake of radiolabeled DX-619 (1.08 MBq/mg; Daiichi
Pharmaceutical Co., Ltd., Tokyo, Japan) by human PMNs was
determined by means of a velocity gradient centrifugation
technique described by Klempner and Styrt (9). PMNs were
incubated with different concentrations (1 to 40 g/ml) of
DX-619. After different incubation times at 37°C, cell-associ-
ated antimicrobial agent concentrations were calculated and
expressed as ratios of cellular to extracellular concentration
(C/E ratios) (11). The efflux of PMN-associated DX-619 was
also studied. All assays were performed in duplicate with
PMNs from four different donors. Data were expressed in
terms of means  standard deviations. Differences among
groups were compared by analysis of variance, with statistical
significance being assessed at a P value of 0.05.
Figure 1 shows the kinetics of DX-619 uptake by and efflux
from human PMNs. The uptake of DX-619 by human PMNs
was a rapid process. DX-619 was highly concentrated in human
PMNs, reaching intracellular concentrations 10 times higher
than the extracellular concentrations reached after 20 min of
incubation at 37°C. C/E ratios for DX-619 were similar to
those observed for moxifloxacin, gemifloxacin, sparfloxacin,
and trovafloxacin and slightly higher than those observed for
other quinolones, such as ofloxacin, levofloxacin, and cipro-
floxacin (5, 6, 12–15). The efflux of DX-619 from human PMNs
was also a rapid process; when the extracellular antimicrobial
was removed, PMN-associated DX-619 decreased 90% after
10 min of incubation at 37°C. The effect of different extracel-
lular concentrations on the uptake of DX-619 by PMNs were also
evaluated. Cell-associated DX-619 was not saturable at extracel-
lular concentrations ranging from 1 to 40 g/ml (data not shown).
Further studies to elucidate the mechanism of DX-619 up-
take by PMNs were performed as described previously (12).
The influences of cell viability, environmental temperature
(4°C versus 37°C), and external pH (5 to 8) were evaluated. We
also studied the effects of metabolic inhibitors (sodium fluo-
ride, 1.5 mM; sodium cyanide, 1.5 mM; carbonyl cyanide m-
chlorophenylhydrazone, 0.015 mM; and 2,4-dinitrophenol, 0.1
mM [Sigma Chemical Co., St. Louis, Mo.]), membrane stimuli
(phorbol myristate acetate [PMA] [200 nM; Sigma] and either
opsonized zymosan [0.9 mg/liter; Sigma] or S. aureus ATCC
25923), and potential competitive substrates adenosine (1
mM), L-lysine (1 mM), and D-glucose (1 mM) on DX-619
uptake by human PMNs.
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FIG. 1. DX-619 uptake by human PMNs and efflux of PMN-asso-
ciated DX-619 after removal of the extracellular drug (n  4). The
extracellular concentration was 2 g/ml. Error bars indicate standard
deviations.
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DX-619 uptake was temperature dependent (C/E ratios, 1.2 
0.4 versus 9.9  1.2) and significantly increased at acid pH
(data not shown). Among the inhibitors evaluated, sodium
cyanide and m-chlorophenylhydrazone significantly impaired
intracellular penetration of DX-619 (C/E ratios, 3.5  0.7 and
5.4  1.1, respectively; C/E ratio for the control, 10.1  0.9). It
is interesting that even an inhibitor of mitochondrial oxidative
metabolism, such as sodium cyanide, decreased the uptake of
DX-619 by PMNs since such cells have few mitochondria, as
they are not dependent on oxidative metabolism for energy
(12). This phenomenon could be related to secondary or minor
activity of this inhibitor in other metabolic functions of phago-
cytes. However, preincubating the PMNs with sodium fluoride,
an inhibitor of glycolysis (a major source of energy for the
PMNs), did not affect their DX-619 uptake. These data point
to the fact that a possible active mechanism could be partially
involved in the uptake of this quinolone by human PMNs.
Similar results were previously described for ofloxacin, levofloxa-
cin, and moxifloxacin, all of which require an active process (13,
15). The uptake of other quinolones, such as sparfloxacin and
trovafloxacin, by human PMNs was not affected by any of these
parameters, and a typically passive mechanism is displayed (5, 14).
Particle phagocytosis or soluble membrane stimuli may
modify the uptake of an antimicrobial agent by human PMNs.
For DX-619, we observed a significant increase in its intracel-
lular accumulation when human PMNs were stimulated with
the soluble stimulus PMA (C/E ratios, 12.7  1.7 versus 9.7 
1.1). The phagocytosis of opsonized Staphylococcus aureus or
zymosan, however, did not modify the uptake. This divergent
effect could be related to the fact that PMN activation by
opsonized particles differs from that by PMA (10). The find-
ings presented suggest that DX-619 uptake is mediated by both
active and passive diffusion across the cytoplasmic membrane
of the PMN.
The intracellular activity of DX-619 compared with that of
ciprofloxacin against S. aureus was evaluated in a 3-h assay
using a previously described method (11). The MICs/mini-
mal bactericidal concentrations of ciprofloxacin (Bayer AG,
Leverkusen, Germany) and DX-619 against S. aureus ATCC
25923 were 0.25/0.5 and 0.001/0.003 g/ml, respectively. Data
were expressed as percentages of surviving staphylococci rela-
tive to control levels (without antimicrobial agents) at 3 h
(means  standard deviations). At extracellular concentrations
of at least 0.0125 g/ml, DX-619 showed significant intracel-
lular activity against S. aureus. At all extracellular concentra-
tions evaluated, the intracellular activity of DX-619 was signif-
icantly higher than that observed for ciprofloxacin (Fig. 2). The
intracellular activity of DX-619 was dose dependent and
greater than that of ciprofloxacin. This effect was partially due
to the higher bactericidal activity of this antimicrobial against
the strain evaluated.
In summary, DX-619 penetrates into human PMNs, reach-
ing intracellular concentrations several times higher than the
extracellular concentrations reached while remaining intracel-
lularly active. A potentially active mechanism may be involved
in the uptake of DX-619 by human PMNs. The high antimi-
crobial activity of this quinolone added to the properties ob-
served in this study enlarges the potential use of DX-619.
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FIG. 2. Activities of DX-619 and ciprofloxacin against intracellular
S. aureus in human PMNs (n  4). Data are expressed as percentages
of surviving bacteria after 3 h of incubation relative to controls without
antimicrobial agents (means  standard deviations [error bars]). *, P
was 0.05 relative to ciprofloxacin.
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